Evidence for a role of endogenous neurotensin in the initiation of amphetamine sensitization

Neuropharmacology

Volumn 39, Issue 10, 2000, Pages 1880-1892

  Rompré, Pierre Paul ^a   Perron, Stéphane ^a  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

Amphetamine; Locomotion; Neurotensin; Sensitization; SR 48692

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; AMPHETAMINE; NEUROTENSIN; NEUROTENSIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG SENSITIZATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; MALE; MOTOR ACTIVITY; NEUROTENSIN; PYRAZOLES; QUINOLINES; RATS; RATS, LONG-EVANS; RECEPTORS, NEUROTENSIN; TIME FACTORS;

EID: 0034123906     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00269-5     Document Type: Article

References (53)

1. Azzi M., Gully D., Heaulme M., Bérod A., Pélaprat D., Kitabgi P.et al. Neurotensin receptor interaction with dopaminergic systems in the guinea-pig brain shown by neurotensin receptor antagonists. European Journal of Pharmacology. 255:1994;167-174.
2. Boudin H., Pélaprat D., Rostène W., Beaudet A. Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor. Journal of Comparative Neurology. 373:1996;76-89.
3. 3H]dopamine release in rat striatal slices and mesencephalic cultures. European Journal of Pharmacology. 253:1994;289-291.
4. Chalon P., Vita N., Kaghad M., Guillemot M., Bonnin J., Delpech B.et al. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Letters. 386:1996;91-94.
5. Choi S.-Y., Chae H.-D., Park T.-J., Ha H., Kim K.-T. Characterization of high affinity neurotensin receptor NTR1 in HL-60 cells and its down regulation during granulocytic differentiation. British Journal of Pharmacology. 126:1999;1188-1199.
6. Crawley J.N. Attenuation of dark-induced hyperlocomotion by a cholecystokinin antagonist in the nucleus accumbens. Brain Research. 473:1988;398-400.
7. Dubuc I., Costentin J., Terranova J.P., Barnouin M.C., Soubrié P., Le Fur G.et al. The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes. British Journal of Pharmacology. 112:1994;352-354.
8. Dubuc I., Sarret P., Labbé-Jullié C., Botto J.-M., Honoré E., Bourdel E.et al. Identification of the receptor subtype involved in the analgesic effect of neurotensin. Journal of Neuroscience. 19:1999;503-510.
9. During M.J., Bean A.J., Roth R.H. Effects of CNS stimulants on the in vivo release of the colocalized transmitters, dopamine and neurotensin, from rat prefrontal cortex. Neuroscience Letters. 140:1992;129-133.
10. Elliott P.J., Nemeroff C.B. Repeated neurotensin administration in the ventral tegmental area: effects on baseline and D-amphetamine-induced locomotor activity. Neuroscience Letters. 68:1986;239-244.
11. Fernández R., Sabater R., Sáez J.A., Montes R., Alba F., Ferrer J.M.R. Mediation by neurotensin-receptors of effects of neurotensin on self-stimulation of the medial prefrontal cortex. British Journal of Pharmacology. 119:1996;299-302.
12. Gully D., Canton M., Boigegrain R., Sanjean F., Molimard J.-C., Poncelet M.et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proceedings of the National Academy of Sciences of the United States of America. 90:1993;65-69.
13. 3H]dopamine release evoked by KCl versus electrical stimulation. Neuropharmacology. 36:1997;1447-1454.
14. Hertel P., Mathé J.M., Nomikos G.G., Iurlo M., Mathé A.A., Svensson T.H. Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behavioral Brain Research. 72:1995;103-114.
15. Hökfelt T., Everitt B.J., Theodorsson-Norheim E., Goldstein M. Occurrence of neurotensin-like immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons. Journal of Comparative Neurology. 222:1984;543-549.
16. Horger B.A., Taylor J.R., Elsworth J.D., Roth R.H. Preexposure to, but not cotreatment with, the neurotensin antagonist SR 48692 delays the development of cocaine sensitization. Neuropsychopharmacology. 11:1994;215-222.
17. Kahn D., Abrams G.M., Zimmerman E.A., Carraway R., Leeman S.E. Neurotensin neurons in the rat hypothalamus: an immunocytochemical study. Endocrinology. 107:1980;47-54.
18. Kalivas P.W. Sensitization to repeated enkephalin administration into the ventral tegmental area of the rat. II. Involvement of the mesolimbic dopamine system. Journal of Pharmacology and Experimental Therapeutics. 235:1985;544-550.
19. Kalivas P.W., Duffy P. Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens. Journal of Neuroscience. 10:1990;2940-2949.
20. Kalivas P.W., Duffy P. A comparison of axonal and somatodendritic dopamine release using in vivo dialysis. Journal of Neurochemistry. 56:1991;961-967.
21. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Research Review. 16:1991;223-244.
22. Kalivas P.W., Taylor S. Behavioral and neurochemical effect of daily injection with neurotensin into the ventral tegmental area. Brain Research. 358:1985;70-76.
23. Kalivas P.W., Weber B. Amphetamine injection into the ventral mesencephalon sensitizes rats to peripheral amphetamine and cocaine. Journal of Pharmacology and Experimental Therapeutics. 245:1988;1095-1102.
24. Kalivas P.W., Burgess S.K., Nemeroff C.B., Prange A.J. Jr. Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat. Neuroscience. 8:1983;495-505.
25. Kalivas P.W., Sorg B.A., Hooks M.S. The pharmacology and neural circuitry of sensitization to psychostimulants. Behavioral Pharmacology. 4:1993;315-334.
26. Kitabgi P. Neurotensin modulates dopamine neurotransmission at several levels along brain dopaminergic pathways. Neurochemistry International. 14:1989;111-119.
27. Koob G.F., LeMoal M. Drug abuse. Hedonic homeostatic dysregulation. Science. 278:1997;52-58.
28. Labbé-Jullié C., Dubuc I., Brouard A., Doulut S., Bourdel E., Pelaprat D.et al. In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes. Journal of Pharmacology and Experimental Therapeutics. 268:1994;328-336.
29. Laitinen K., Crawley J.N., Mefford I.N., De Witte Ph. Neurotensin and cholecystokinin microinjected into the ventral tegmental area modulate microdialysate concentrations of dopamine and metabolites in the posterior nucleus accumbens. Brain Research. 523:1990;342-346.
30. Mazella J., Zsurger N., Navarro V., Chabry J., Kaghad M., Caput D.et al. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. Journal of Biological Chemistry. 273:1998;26273-26276.
31. Nicot A., Rostène W., Berod A. Neurotensin receptor expression in the rat forebrain and midbrain: a combined analysis by in situ hybridization and receptor autoradiography. Journal of Comparative Neurology. 341:1994;407-419.
32. Nicot A., Rowe W.B., DeKloet E.R., Betancur C., Jessop D.S., Lightman S.L.et al. Endogenous neurotensin regulates hypothalamic-pituitary-adrenal axis activity and peptidergic neurons in the rat hypothalamic paraventricular nucleus. Journal of Neuroendocrinology. 9:1997;263-269.
33. Nouel D., Faure M.-P., St-Pierre J.-A., Alonso R., Quirion R., Beaudet A. Differential binding profile and internalization process of neurotensin via neuronal and glial receptors. Journal of Neuroscience. 17:1997;1795-1803.
34. Piazza P.V., LeMoal M. The role of stress in drug self-administration. Trends in Pharmacological Sciences. 19:1998;67-74.
35. Pinnock R.D., Woodruff G.N. The non-peptide neurotensin receptor antagonist SR48692 is not a potent antagonist of neurotensin(8-13) responses of rat substantia nigra neurones in vitro. Neuroscience Letters. 172:1994;175-178.
36. Poncelet M., Gueudet C., Gully D., Soubrié P., Le Fur G. Turning behavior induced by intrastriatal injection of neurotensin in mice. Sensitivity to non-peptide neurotensin antagonists. Naunyn-Schmiedeberg's Archives of Pharmacology. 349:1994;57-60.
37. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration. A review and evaluation of animal models of amphetamine psychosis. Brain Research. 396:1986;157-198.
38. Rompré P.-P. Repeated activation of neurotensin receptors sensitizes to the stimulant effect of amphetamine. European Journal of Pharmacology. 328:1997;131-134.
39. Rompré P.-P., Perron S. The selective neurotensin receptor antagonist, SR-48692, blocks the development of amphetamine sensitization. Society of Neuroscience Abstract. 23:1997;2145.
40. Rompré P.-P., Boye S.M., Moisan J. Activation of neurotensin receptors in the prefrontal cortex stimulates midbrain dopamine cell firing. European Journal of Pharmacology. 341:1998;169-172.
41. Santucci V., Gueudet C., Steinberg R., Le Fur G., Soubrié P. Involvement of cortical neurotensin in the regulation of rat meso-cortico-limbic dopamine neurons. Evidence from changes in the number of spontaneously active A10 cells after neurotensin receptor blockade. Synapse. 26:1997;370-380.
42. Seroogy K.B., Mehta A., Fallon J.H. Neurotensin and cholecystokinin coexistence within neurons of the ventral mesencephalon projections to forebrain. Experimental Brain Research. 68:1987;277-289.
43. Seutin V., Massotte L., Dresse A. Electrophysiological effects of neurotensin on dopaminergic neurones of the ventral tegmental area of the rat in vitro. Neuropharmacology. 28:1989;949-954.
44. Steinberg R., Brun P., Fournier M., Souilhac J., Rodier D., Mons G.et al. SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission. Neuroscience. 59:1994;921-929.
45. Steinberg R., Rodier D., Mons G., Gully D., Le Fur G., Soubrié P. SR 49692-sensitive neurotensin receptors modulate acetylcholine release in the rat striatum. Neuropeptides. 29:1995;27-31.
46. Stewart J., Badiani A. Tolerance and sensitization to the behavioral effects of drugs. Behavioral Pharmacology. 4:1993;289-312.
47. Stoessl A.J. Effects of neurotensin in a rodent model of tardive dyskinesia. Neuropharmacology. 34:1995;457-462.
48. Studler J.M., Kitabgi P., Tramu G., Hervé D., Glowinski J., Tassin J.P. Extensive co-localization of neurotensin with dopamine in rat meso-cortico-frontal dopaminergic neurons. Neuropeptides. 11:1988;95-100.
49. Tanaka K., Masu M., Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron. 4:1990;847-854.
50. Uhl G.R., Kuhar M.J., Snyder S.H. Neurotensin: immunohistochemical localization in rat central nervous system. Proceedings of the National Academy of Sciences of the United States of America. 74:1977;4059-4063.
51. 1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area. Journal of Neuroscience. 16:1996;2411-2420.
52. Wagstaff J.D., Bush L.G., Gibb J.W., Hanson G.R. Endogenous neurotensin antagonizes methamphetamine-enhanced dopaminergic activity. Brain Research. 665:1994;237-244.
53. Wolf M.E., Dahlin S.L., Hu X.T., Xue C.J., White K. Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioral sensitization to amphetamine. Comparison with N-methyl-D-aspartate antagonists. Neuroscience. 69:1995;417-439.